Abstract
This protocol outlines an updated systematic review and meta-analysis comparing aspirin versus P2Y12 inhibitor monotherapy for long-term maintenance in patients with ischemic heart disease following 12 months of dual antiplatelet therapy (DAPT) after coronary stenting.
Introduction
Percutaneous Coronary Intervention (PCI) with stenting is a cornerstone of treatment for ischemic heart disease. To prevent stent thrombosis, patients are traditionally prescribed Dual Antiplatelet Therapy (DAPT)—a combination of aspirin and a P2Y12 inhibitor—for approximately 12 months. Following this period, patients transition to lifelong monotherapy. While aspirin has been the historical gold standard, the emergence of potent P2Y12 inhibitors like clopidogrel, ticagrelor, and prasugrel has raised questions about which agent provides the best long-term protection.
The primary clinical challenge lies in balancing the prevention of Major Adverse Cardiac Events (MACE), such as myocardial infarction and stroke, against the risk of major bleeding complications. This protocol establishes the methodology for a study intended to provide a definitive, updated consensus on this therapeutic choice.
Methodology
This study is designed as a systematic review and meta-analysis of existing clinical literature. The authors will employ a rigorous framework to ensure data integrity and minimize bias.
Search Strategy and Inclusion Criteria
The research team will conduct a comprehensive search across major medical databases, conference proceedings, and expert communications. The review will include both Randomized Controlled Trials (RCTs) and prospective observational studies. Eligible studies must involve patients who have completed a standard 12-month course of DAPT post-PCI and subsequently transitioned to either aspirin or P2Y12 inhibitor monotherapy.
Quality Assessment and Statistical Analysis
To ensure the reliability of the findings, the quality of included RCTs will be evaluated using the Cochrane risk of bias tool, while observational studies will be assessed via the Newcastle-Ottawa Scale. The meta-analysis will calculate pooled estimates based on participant numbers and event rates (deaths, MACE, and bleeding). Subgroup analyses are planned to account for the specific type of P2Y12 inhibitor used and the duration of patient follow-up.
Discussion: The "Aspirin-Free" Hypothesis
A central theme of this research is the potential shift toward an "aspirin-free" maintenance strategy. There is a growing hypothesis that P2Y12 inhibitors may offer superior secondary prevention while being "gentler" on the gastrointestinal tract, thereby reducing the risk of bleeding compared to long-term aspirin use.
The study emphasizes the concept of "net clinical benefit." In modern cardiology, a drug's success is measured not just by its ability to prevent ischemia, but by its overall safety profile. A reduction in heart attacks is of limited value if it is offset by an increase in fatal intracranial or gastrointestinal bleeds. Furthermore, the protocol acknowledges the heterogeneity among P2Y12 inhibitors; for instance, the variable metabolism of clopidogrel versus the higher potency of ticagrelor may lead to different clinical outcomes.
Limitations and Future Directions
As this is a protocol, the primary limitation is the absence of final results. The eventual meta-analysis will also face challenges related to data variability between RCTs and observational data. Additionally, as stent technology (such as the latest generation of drug-eluting stents) continues to evolve, the baseline risk of thrombosis may change, potentially impacting the relative efficacy of these monotherapies.
Once completed, the results of this systematic review and meta-analysis are expected to play a crucial role in shaping future clinical guidelines for the long-term management of patients with ischemic heart disease.
Conclusion
By pre-registering this protocol, the authors ensure transparency and methodological rigor. This study aims to resolve the long-standing debate between aspirin and P2Y12 inhibitor monotherapy, providing clinicians with the evidence needed to optimize long-term outcomes for post-PCI patients.
Summary updated